1. Adenocarcinoma arising in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor therapy.
- Author
-
Anjiki H, Mukaisho KI, Kadomoto Y, Doi H, Yoshikawa K, Nakayama T, Vo DT, Hattori T, and Sugihara H
- Subjects
- Cocarcinogenesis, Drug Administration Schedule, Gastrins blood, Gastritis, Atrophic complications, Gastroscopy, Humans, Hyperplasia, Male, Middle Aged, Polyps diagnosis, Polyps etiology, Proton Pump Inhibitors administration & dosage, Stomach Neoplasms diagnosis, Adenocarcinoma etiology, Helicobacter Infections complications, Helicobacter pylori, Proton Pump Inhibitors adverse effects, Stomach Neoplasms etiology
- Abstract
We report a case of developing multiple adenocarcinoma foci in multiple hyperplastic polyps in a patient with Helicobacter pylori infection and hypergastrinemia during long-term proton pump inhibitor (PPI) therapy. A 57-year-old man, who was undergoing hemodialysis for chronic renal failure, underwent an upper gastrointestinal endoscopy to elucidate the cause of anemia. Atrophic gastritis with H. pylori infection and multiple adenocarcinoma foci in multiple hyperplastic polyps were found in the endoscopic and histological examinations. Enterochromaffin-like micronests and parietal cell protrusion in the background of the polyps suggested the existence of hypergastrinemia. The serum gastrin level was markedly high-10,206 pg/ml (normal range 37-172 pg/ml). The cause of this marked hypergastrinemia was not autoimmune gastritis and gastrinoma. After discontinuing PPI therapy and successful eradication of H. pylori, the serum gastrin level decreased to normal range. These findings indicate that hypergastrinemia may be caused by long-term PPI therapy in patients with H. pylori infection. This case suggests that hypergastrinemia may mediate gastric carcinogenesis in patients with H. pylori infection.
- Published
- 2017
- Full Text
- View/download PDF